June 24, 2026 02:21 AM GMT Pharmaceuticals | Japan M Idea Jul-Dec 2026 Catalysts for Mid- cap Pharma/Generics We provide a preview of catalysts for our mid-cap pharma coverage in Jul-Dec 2026. Expectations are high for the new drug pipelines of Sumitomo Pharma, Nippon Shinyaku, Kaken & Santen. Of these, we think investment appeal, incl. shareholder return prospects, is highest for Sumi Pharma & Santen. Watch Towa's progress on its volume strategy in generics. Morgan Stanley MUFG Securities Co., Ltd.+ Jaeheo ...